TABLE 1.
Comparison of clinical sensitivity for detection of CIN2+ and CIN3+ with clinical specificity for ≤CIN1 of Anyplex, hc2, and cobasa
| Study group and test | Clinical sensitivity (%) for: |
Clinical specificity (%) | |
|---|---|---|---|
| CIN2+ | CIN3+ | ||
| Women ≥30 years old | |||
| Anyplex | 96.9 (95/98; 91.3–99.4) | 98.5 (65/66; 91.8–100.0) | 94.1 (951/1,011; 92.4–95.4) |
| hc2 | 95.9 (94/98; 89.9–98.9) | 97.0 (64/66; 89.5–99.6) | 92.7 (937/1,011; 90.9–94.2) |
| cobas | 96.9 (95/98; 91.3–99.4) | 97.0 (64/66; 89.5–99.6) | 93.9 (944/1,005; 92.2–95.3) |
| Total study population | |||
| Anyplex | 96.9 (123/127; 92.1–99.1) | 98.8 (81/82; 93.4–100.0) | 91.5 (1,111/1,214; 89.8–93.0) |
| hc2 | 96.1 (122/127; 91.1–98.7) | 97.6 (80/82; 91.5–99.7) | 90.1 (1,094/1,214; 88.3–91.8) |
| cobas | 96.1 (122/127; 91.1–98.7) | 97.6 (80/82; 91.5–99.7) | 91.4 (1,103/1,207; 89.7–92.9) |
a
Testing was performed on the total study population and on women ≥30 years old. Data in parentheses are total positive for sensitivity or specificity out of the total number of samples and 95% CI.